## Clinical Trials Summary for out of hours Important Reference



Acronym study title	Decipher Study
Study Details	DECIPHER: Developing ctDNA guided adjuvant therapy for gastro- oesophageal cancer
	A single arm phase II trial of trastuzumab deruxtecan in patients with gastro-oesophageal adenocarcinoma cancer who are ctDNA and HER2 positive
Principal Investigator PI Sub PI's	PI – Dr Catherine Mitchell Sub Investigator – Dr Majeed Dr Ana Ferreira
Research Nurse Team	Research Nurse - Sirjana Devkota CTSO - Nathan Fish
Drug therapy	Transtuzumab deruxtecan 6.4mg/kg every 21 days for 8 cycles.
In the event that a patient calls this hotline for Advise	NHS chemotherapy helpline.